BioCentury
ARTICLE | Clinical News

HspE7 plus Poly-ICLC: Phase II start

May 26, 2008 7:00 AM UTC

Mid-year, Nventa plans to start a double-blind, placebo-controlled, North and South American Phase II trial in patients with human papillomavirus (HPV) type 16-induced CIN 2/3. ...